Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00159666 · ClinicalTrials.gov registry record · Phase 4
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
A Phase 4 study of Post Herpetic Neuralgia, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT00159666 is a Phase 4 study of Post Herpetic Neuralgia that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 255 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT00159666, a Phase 4 study of Post Herpetic Neuralgia, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
Conditions Studied
Interventions
- DRUG pregabalin
Study Locations (20)
Other
- Pfizer Investigational Site - Berlin
- Pfizer Investigational Site - Bochum
- Pfizer Investigational Site - Düsseldorf
- Pfizer Investigational Site - Frankfurt
- Pfizer Investigational Site - Göppingen
- Pfizer Investigational Site - Hamburg
Arizona
- Pfizer Investigational Site - Phoenix
Arkansas
- Pfizer Investigational Site - Little Rock
California
- Pfizer Investigational Site - Duarte
Colorado
- Pfizer Investigational Site - Denver
Florida
- Pfizer Investigational Site - Palm Beach Gardens
Illinois
- Pfizer Investigational Site - Oak Brook
Mississippi
- Pfizer Investigational Site - Flowood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2004-10 |
| Est. Completion | 2006-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00159666
The ClinicalTrials.gov registry entry for NCT00159666 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post Herpetic Neuralgia appearing as the primary indexed condition, and to 1 intervention - of which pregabalin is the first listed.
NCT00159666 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00159666 about?
NCT00159666 is a clinical study titled "Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia". The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
What is the current status of trial NCT00159666?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 255 participants. The study started on 2004-10. Estimated completion is 2006-06.
What conditions does trial NCT00159666 study?
This clinical trial studies the following conditions: Post Herpetic Neuralgia.
What interventions are being tested in trial NCT00159666?
The interventions under investigation include: pregabalin (DRUG).
Who is sponsoring clinical trial NCT00159666?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00159666 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Post Herpetic Neuralgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.